Please login to the form below

Not currently logged in
Email:
Password:

Sepracor's epilepsy drug cuts seizures

Sepracor has said its esclicarbazepine acetate drug causes a significant reduction in the frequency of seizures
Sepracor has said that results of its randomised, double-blind trials involving 1,049 patients show that compared to a placebo, patients given its esclicarbazepine acetate drug (in either 800mg or 1200mg doses) experience a significant reduction in the frequency of seizures.

The phase III trials involved patients, who despite being treated with epilepsy drugs, experienced four or more partial seizures per month. Over a 12-week period, patients receiving the 800mg dosage showed a 35.4 per cent relative reduction in seizure frequency. Patients receiving the 1200mg dose showed a 38.8 per cent reduction.

In an open-label follow up study lasting 52 weeks, patients who were given esclicarbazepine acetate showed statistically significant improvements in quality of life.

Esclicarbazepine acetate is designed to be used in combination with other anti-epileptic drugs. It is a sodium channel blocker that works by blocking electrical signals in the brain to reduce the frequency of partial-onset seizures.

19th June 2008

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Videum Health

Videum Health is a premium video platform that offers brands innovative engagement strategies to reach targeted healthcare audiences on a...

Latest intelligence

ABPI2018
The NHS and ABPI at 70: inching closer to the triple win
The NHS and UK pharma’s ABPI both turn 70 this year. After years of transactional relationships, there’s a will to work more closely - but friction on prices and value...
What pharma marketers can learn from behavioural science
Pharma behavioural science and traditional emotional marketing create a powerful mix of techniques that have impact on real lives....
NEW EU DATA PROTECTION REGULATION POISED TO CHANGE DATA PRIVACY LANDSCAPE
NEW EU DATA PROTECTION REGULATION POISED TO CHANGE DATA PRIVACY LANDSCAPE The bold digital clock featured on the EUGDPR (EU General Data Protection Regulation)1 website indicates – to the second...

Infographics